Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Clasificación en acciones #16898
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Precio por acción
$2.46
Capitalización bursátil
$268.65M
Cambio (1 día)
-1.73%
Cambio (1 año)
-57.06%
País
CN
Comercio VISEN Pharmaceuticals (2561)

Categoría

Historial de rendimiento por dividendo de VISEN Pharmaceuticals (2561)
Rendimiento por dividendo (TTM) de VISEN Pharmaceuticals (símbolo bursátil: 2561) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de VISEN Pharmaceuticals (2561) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras